Drug intelligence / Profile preview

Y-1

Development stage: Unknown
Lead developer: Nanjing Ningdan New Drug Technology
Modality: Small Molecules
Administration: Intravenous

Overview

Y-1 is an investigational drug administered via injection, currently undergoing a Phase I clinical trial for the treatment of recurrent primary intracranial malignant tumors. The trial is designed as a single-arm, open-label, sequential dose-increasing study to evaluate its tolerance and pharmacokinetics after single and multiple administrations. The drug is being developed by Nanjing Ningdan New Drug Technology Co., Ltd. and Beijing Tiantan Hospital Affiliated to Capital Medical University. The specific mechanism of action for Y-1 has not been disclosed in the provided context or search results.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPC5 (Transient receptor potential Canonical-5)

Beyond the preview

Go deeper on Y-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y-1.

Explore the full profile